To accelerate/expedite the entire portfolio and platforms of SRPT. Obviously, he was failing. Good news is I doubt it has anything to do with Etep. We have all complained as to why we were not getting any updates on the other Exons and platforms. Now perhaps we know. I believe Chris and the BOD were frustrated with the pace of things, along with possible differing strategies and approaches. He was probably an ineffective and somewhat incompetent scientific leader....but maybe a good scientist. This is all conjecture, but termination PR's are a lot different than resignation PR's (family time, other opportunities etc..). I just hope some advancements were under way, regardless of today's news. He was there 7 months...let's hope progress was made in spite.
Supposed clarification on the top scientist leaving. I cannot open it....if anyone can could you please copy and paste. I'll keep trying. TIA
Certainly a valid concern. I truly believe you are being sincere with the intention of your post.. That is why the sample size has always created tension. If there were 200 children in the trial and 100 showed some level of efficacy, this would be approved yesterday! We will only learn the true potential of this drug post AA with a large ongoing confirmatory trial. Of course, it certainly wouldn't hurt if Chris gave us a platform update DMD, Exon, infectious disease etc... The silence from the company on all fronts is disconcerting and suspect (for good or bad). I am in and I'll assume things are running full swing. The strong longs will prevail!
That is why when you believe in a company ...you hold with conviction. ICPT and today, PBYI. I love dropping in on those message boards and watch the celebration. Congrats to PBYI longs and more importantly, breast cancer patients.
Fair enough. What disturbs me, is why their are no partnerships with such compelling data. Seems to me, if big pharma wanted to deliver their drugs in the most efficacious and safe manner....why are they not seeing the same data as us little retail people. Perhaps they are waiting in the flanks for more data and we are close. I do not want a buyout, but at .50 cents Merck could take it all with relative pocket change.
An ongoing PHASE 2 trial
Technology released from another company
One Product....Yes, One product!
15 presentations in the last 3 months....negative 2 cent pps per presentation
No one is buying the hype
Most small bios are down today
This is a lottery play....Not an investment
Yellen short term effect!
I am long....go figure! One product that can reverse cancer....all the above forgotten. The data as I know it hasn't changed. If you buy now, you are buying 40% below our CEO. This is risky and all that is on the table is being emotionally tied to the short term pps. You have to decide to sell, hold or buy. My price target is 1.50 by EOY, Punit and the secondary raise have at least the same pps target. GLTA
I promoted Tacrine/Cognex (about 20 to 25 years ago, for the first and only treatment for Alzheimers. It helped fewer than 30% by MAYBE slowing the progression of disease and had a lot of liver toxicity issues. Everyone tried it who met the diagnosis criteria and even those who didn't. SGPT/SGOT (liver transaminase levels) had to be monitored monthly and the drug was administered QID (ironic for Alzheimer's). Bottom line, we have children that have better odds for success and a clean AE profile. If Tacrine was approved, how could Etep not get approval.especially with the new FDA unmet needs mandate currently being deployed.
Black Box: If DMD is diagnosed and not treated, the following will occur:
1) 0 to 5 years. Decline and deterioration is muscle mass and quality of life.
2) 5 to 10 years. Loss of ambulation and cardiopulmonary distress
3) 10 to 15 years. Care giver dependence and Hospice
4) 15 years and beyond. Nearly 100% mortality probability
That was certainly not the impetus for my investment strategy, I have been in this stock for 12 years. It is simply a curiosity question and perhaps a character/judgment gauge regarding our CEO going forward. Not trying to be totally negative, just playing Columbo.
Can anyone provide your best WAG as to what Chris was referring to months ago, about an unprecedented exciting development. OR, was this just an amateurish overly zealous remark by an overly excited inexperienced CEO. Hopefully, his excitement and remarks are not unfounded and can potentially come to fruition. This mystery proclamation by our CEO (may be blunder) has driven me crazy. If in fact, there is something unprecedented and game changing....it would be a good time to unveil it.
Good point. I also believe there could be a faction of children in large scale use that may elicit a reversal response. Again, 20% reversal/improvement, 20% stabilization and 30% slowing of progression = a collective 70% response rate, with an extremely good safety profile...almost pristine...in an unmet disease state! Also, as Tred pointed out, if the cardiopulmonary parameters are preserved and even improved, this can account for another life style change that their historic counterparts have not been provided opportunity. Finally, as we take the next step into unveiling additional Exon therapies...;.more children may be helped. This is a great start and we do not have all the answers yet....Even with Exon 51. Keep the faith.
DMD (EXON 51)
DMD (EXON 53)
DMD (EXON 45)
DMD (EXON 50)
DMD (EXON 44)
DMD (EXON 52)
DMD (EXON 55)
DMD (EXON 8)
KEY Clinical PROGRAMS
EXON SKIPPING FOR DUCHENNE
AVI-7288 FOR MARBURG
AVI-7100 FOR INFLUENZA
© 2014 Sarepta Therapeutics
No mistake that this is not fun to watch. However, this is certainly not SRPT specific. Many Bio techs are getting pummeled today. I have been adding in intervals, because I am not sure where the bottom will occur. I do know the top has not changed long term.